Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adlai Nortye Starts Phase III Trial of Pan- PI3K Inhibitor in Head and Neck Carcinoma

publication date: Apr 15, 2021

Adlai Nortye, a Hangzhou-New Jersey biopharma, has dosed the first patient in a global Phase III trial of Buparlisib at the Shanghai Eastern Hospital Medical Center. The trial will test Buparlisib, an oral pan-PI3K inhibitor, as a second-line therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients must have disease that progressed after a previous PD-1/PD-L1 treatment. Adlai Nortye said the trial is the first global multicenter Phase III trial of a PI3K inhibitor as an HNSCC therapy. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here